← Latest news 
Semaglutide API prices tumble as GLP-1 demand surges and generics flood markets
Economy
Published on 24 April 2026
More factories and expiring patents may cut prices further
Semaglutide API prices are falling sharply as global demand for weight-loss drugs like Ozempic and Wegovy drives rapid manufacturing expansion. With patents set to expire in key markets and Indian companies rolling out lower-priced generics, analysts expect additional price softening. The shift could widen access to these GLP-1 therapies for patients in the months ahead.
- Semaglutide API prices drop amid a global GLP-1 weight-loss demand boom
- Manufacturing capacity has ramped up quickly to meet surging orders
- Patent expiries in key markets are easing supply constraints
- Lower-priced Indian generics may push prices down further
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times